Contineum Therapeutics (CTNM) to Release Earnings on Wednesday

Contineum Therapeutics (NASDAQ:CTNM) is expected to release its earnings data before the market opens on Wednesday, February 5th. Analysts expect Contineum Therapeutics to post earnings of ($0.44) per share for the quarter.

Contineum Therapeutics (NASDAQ:CTNM) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.01. On average, analysts expect Contineum Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Contineum Therapeutics Price Performance

Shares of NASDAQ:CTNM opened at $9.79 on Monday. Contineum Therapeutics has a 52 week low of $9.76 and a 52 week high of $22.00. The company’s 50 day moving average is $13.44 and its two-hundred day moving average is $16.40.

Analyst Upgrades and Downgrades

CTNM has been the topic of several recent analyst reports. Robert W. Baird started coverage on Contineum Therapeutics in a report on Tuesday, October 22nd. They issued an “outperform” rating and a $32.00 target price on the stock. Baird R W raised Contineum Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 22nd. Finally, Royal Bank of Canada restated an “outperform” rating and set a $31.00 target price on shares of Contineum Therapeutics in a research note on Thursday, January 9th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Contineum Therapeutics has an average rating of “Buy” and a consensus target price of $29.25.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).